Repligen Corp Stock Prediction
AI-powered sentiment analysis and prediction trends for RGEN, updated each market day.
RGEN AI Sentiment
AI sees no strong directional signal for Repligen Corp stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Sector
Exchange
Market Cap
$6,432,901,192
Cap Tier
Employees
2,000
Headquarters
WALTHAM, MA
Listed Since
April 29, 1986
Website
RGEN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RGEN Volatility
Repligen Corp has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
